Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $15 and keeps a Buy rating on the shares. Revenue came in roughly $3.7M short of the $25.0M consensus, mainly due to a shortfall in the DTC Medicx business, the analyst tells investors. The company is implementing changes to its 2025 plan with greater focus on self-serve, which should alleviate some of the softness in the DTC business, but the company lowered its 2024 outlook to account for the change, the analyst added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $16 from $20 at Roth MKM
- OptimizeRx price target lowered to $8 from $16 at JMP Securities
- OptimizeRx price target lowered to $5 from $11 at Barclays
- OptimizeRx Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance